Surgery for mesothelioma: the evidence base and a pragmatic approach to surgical treatment

Abstract

The authors were invited to provide a summary of the current evidence and an evidence-based approach to practice. Clinical practice guidelines are not available for India and a formal approach to these would require a properly constituted guideline development group rather than an opinion piece from three surgeons. What we have provided is a critical view of current practice and some pointers to a realistic pragmatic approach intended to avoid non-evidence-based practice and excessive harm to no advantage.

This is a preview of subscription content, log in to check access.

Fig. 1

Notes

  1. 1.

    https://www.google.co.uk/search?source=hp&q=australian+meso+guidelines&oq=australian+meso+guidelines&gs_l=psy-ab.3...2553.15894.0.18503.35.30.4.0.0.0.119.2593.27j3.30.0....0...1.1.64.psy-ab..1.33.2522.0..0j35i39k1j0i131k1j0i10k1j0i13k1j0i22i30k1j33i160k1j33i21k1.0.tN6ZgsTa9no

  2. 2.

    http://timesofindia.indiatimes.com/home/environment/pollution/NGT-asks-5-mineral-rich-states-to-survey-all-asbestos-mines/articleshow/48039145.cms April 2016 accessed August 2017.

References

  1. 1.

    van Zandwijk N, Clarke C, Henderson D, et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis. 2013;5:E254–307.

  2. 2.

    Gilham C, Rake C, Burdett G, et al. Pleural mesothelioma and lung cancer risks in relation to occupational history and asbestos lung burden. Occup Environ Med. 2016;73:290–9.

  3. 3.

    Rake C, Gilham C, Hatch J, Darnton A, Hodgson J, Peto J. Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. Br J Cancer. 2009;100:1175–83.

  4. 4.

    Okello C, Treasure T, Nicholson AG, Peto J, Moller H. Certified causes of death in patients with mesothelioma in South East England. BMC Cancer. 2009;9:28.

  5. 5.

    Bruni BM, Pacella A, MazziottiTagliani S, Gianfagna A, Paoletti L. Nature and extent of the exposure to fibrous amphiboles in Biancavilla. Sci Total Environ. 2006;370:9–16.

  6. 6.

    Proietti L, Migliore M, Polosa R, Comba P, Circo C, Di Maria GU. Malignant pleural mesothelioma in housewives in the province of Catania. Recenti Prog Med. 2004;95:365–8.

  7. 7.

    Yamashita Y, Harada H, Mukaida H, Kaneko M. Extrapleural pneumonectomy plus rib resection for malignant pleural mesothelioma: a case report. J Cardiothorac Surg. 2014;9:176.

  8. 8.

    Patel SC, Dowell JE. Modern management of malignant pleural mesothelioma. Lung Cancer (Auckl). 2016;7:63–72.

  9. 9.

    Taioli E, Wolf AS, Camacho-Rivera M, et al. Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients. PLoS One. 2015;10:e0145039.

  10. 10.

    Rice D, Rusch V, Pass H, et al. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol. 2011;6:1304–12.

  11. 11.

    Hasani A, Alvarez JM, Wyatt JM, et al. Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia. J Thorac Oncol. 2009;4:1010–6.

  12. 12.

    Sugarbaker DJ. Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. J Thorac Oncol. 2006;1:175–6.

  13. 13.

    Sugarbaker DJ, Garcia JP, Richards WG, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg. 1996;224:288–94.

  14. 14.

    Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54–63.

  15. 15.

    Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg. 2004;128:138–46.

  16. 16.

    Stewart DJ, Martin-Ucar A, Pilling JE, Edwards JG, O'Byrne KJ, Waller DA. The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma. Ann Thorac Surg. 2004;78:245–52.

  17. 17.

    Waller DA. Malignant mesothelioma-British surgical strategies. Lung Cancer. 2004;45:S81–4.

  18. 18.

    Stewart DJ, Martin-Ucar AE, Edwards JG, West K, Waller DA. Extra-pleural pneumonectomy for malignant pleural mesothelioma: the risks of induction chemotherapy, right-sided procedures and prolonged operations. Eur J Cardiothorac Surg. 2005;27:373–8.

  19. 19.

    Treasure T, Sedrakyan A. Pleural mesothelioma: little evidence, still time to do trials. Lancet. 2004;364:1183–5.

  20. 20.

    Treasure T, Waller D, Tan C, et al. The Mesothelioma and Radical surgery randomized controlled trial: the Mars feasibility study. J Thorac Oncol. 2009;4:1254–8.

  21. 21.

    Cao CQ, Yan TD, Bannon PG, McCaughan BC. A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol. 2010;5:1692–703.

  22. 22.

    Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol. 2007;2:957–65.

  23. 23.

    Utley M, Fiorentino F, Treasure T. Obtaining an upper estimate of the survival benefit associated with surgery for mesothelioma. Eur J Cardiothorac Surg. 2010;38:241–4.

  24. 24.

    Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12:763–72.

  25. 25.

    Weder W, Stahel RA, Baas P, et al. The MARS feasibility trial: conclusions not supported by data. Lancet Oncol. 2011;12:1093–4.

  26. 26.

    Rusch V, Baldini EH, Bueno R, et al. The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: Meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass. J Thorac Cardiovasc Surg. 2013;145:909–10.

  27. 27.

    Bliss JM, Coombes G, Darlison L, et al. The MARS feasibility trial: correspondence. Lancet Oncol. 2011;12:1094–5.

  28. 28.

    Treasure T, Utley M, O'Byrne K. MARS: a sense of perspective and an inconvenient truth. J Thorac Oncol. 2013;8:e48–9.

  29. 29.

    Hiddinga BI, van Meerbeeck JP. Surgery in mesothelioma - where do we go after MARS? J Thorac Oncol. 2013;8:525–9.

  30. 30.

    Lee YC. Surgical resection of mesothelioma: an evidence-free practice. Lancet. 2014;384:1080–1.

  31. 31.

    Bovolato P, Casadio C, Bille A, et al. Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol. 2014;9:390–6.

  32. 32.

    Rena O, Casadio C. Lack of evidence in malignant pleural mesothelioma surgery. Interact Cardiovasc Thorac Surg. 2011;12:347–8.

  33. 33.

    Rena O, Casadio C. Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: A harmful procedure. Lung Cancer. 2012;77:151–5.

  34. 34.

    Rusch VW, Giroux D, Kennedy C, et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol. 2012;7:1631–9.

  35. 35.

    Batirel HF, Metintas M, Caglar HB, et al. Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy. J Thorac Cardiovasc Surg. 2016;151:478–84.

  36. 36.

    Azzouqa AG, Stevenson JP. The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesothelioma. Onco Targets Ther. 2016;9:7247–52.

  37. 37.

    Treasure T, Macbeth F. An exception that proves the rule: recurrence free survival five years after extrapleural pneumonectomy for malignant pleural mesothelioma. J Cardiothorac Surg. 2014;9:181.

  38. 38.

    Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135:620–6.

  39. 39.

    Lang-Lazdunski L, Bille A, Lal R, et al. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol. 2012;7:737–43.

  40. 40.

    Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014;83:240–5.

  41. 41.

    Burt BM, Cameron RB, Mollberg NM, et al. Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality. J Thorac Cardiovasc Surg. 2014;148:30–5.

  42. 42.

    Taioli E, Wolf AS, Flores RM. Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann Thorac Surg. 2015;99:472–80.

  43. 43.

    Teh E, Fiorentino F, Tan C, Treasure T. A systematic review of lung-sparing extirpative surgery for pleural mesothelioma. J R Soc Med. 2011;104:69–80.

  44. 44.

    Flores RM. Pleurectomy decortication for mesothelioma: The procedure of choice when possible. J Thorac Cardiovasc Surg. 2016;151:310–2.

  45. 45.

    Flores RM. The mesothelioma surgery shift. J Thorac Cardiovasc Surg. 2016;151:485–6.

  46. 46.

    Flores RM. The mesothelioma enigma. J Thorac Cardiovasc Surg. 2015;149:1548–9.

  47. 47.

    Cao C, Tian DH, Pataky KA, Yan TD. Systematic review of pleurectomy in the treatment of malignant pleural mesothelioma. Lung Cancer. 2013;81:319–27.

  48. 48.

    Rintoul RC, Ritchie AJ, Edwards JG, et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014;384:1118–27.

  49. 49.

    Tan C, Sedrakyan A, Browne J, Swift S, Treasure T. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg. 2006;29:829–38.

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Tom Treasure.

Ethics declarations

There is no research reported in this paper.

We only summarise and review clinical work already completed and published.

Conflict of interest

The authors declare that they have no conflicts of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Pai, V.B., Rammohan, K.S. & Treasure, T. Surgery for mesothelioma: the evidence base and a pragmatic approach to surgical treatment. Indian J Thorac Cardiovasc Surg 34, 65–71 (2018). https://doi.org/10.1007/s12055-017-0606-y

Download citation

Keywords

  • Malignant mesothelioma
  • Surgical management
  • Surgery